GRAL Stock GRAIL, Inc.
US · NasdaqGSLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Early cancer-detection technology addresses large unmet need and benefits from expanding diagnostic innovation.
Future value: $132.56 (+0.00%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Sector enthusiasm for blood-based cancer screening technologies.
- ▸Above 50-day MA (+27.22%)
- ▸Above 200-day MA — long-term uptrend
- ▾Trading above its price target — limited upside
Is GRAL a buy right now?
Trend: GRAL is trading above the 50-day average (+27.22%), RSI 28 — oversold territory, with a 3-month return of +98.52%.
Valuation & quality: GRAIL, Inc. trades on forward P/E -17.0, price-to-book 2.46; fundamentals show net margin -236.9%, return on equity -16.1%, revenue growth 25.7% year on year.
Analyst consensus: 9 analysts have a mean 12-month price target of $132.56 (-5.3% vs the last close; range $74.00 – $180.00), consensus rating “buy”.
Our screen: WATCH (score 0) — Early cancer-detection technology addresses large unmet need and benefits from expanding diagnostic innovation.
Computed from end-of-day data; not personal advice.
Our track record with GRAL
First flagged in our daily picks as BUY on 2026-10-26 at $132.55 — +5.6% since.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -2.90% | +5.40% | +31.60% | -4.80% | +0.40% | +15.80% | +76.50% | -5.40% |
Fundamentals
Analyst price target
Technical signals
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Sector: Healthcare · Industry: Diagnostics & Research · United States · 910 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.